Industry Insights Online Sources 07 Jan 2026 views ( )

Illumina Launches Connected Multiomics Software Platform to Accelerate Multi-Omics Discovery

On January 6, 2026, Illumina, Inc. (NASDAQ: ILMN) announced the launch of Illumina Connected Multiomics, a powerful cloud-based scientific software platform designed to analyze and visualize large-scale, multi-omics and multimodal biological data. As multi-omics datasets grow rapidly in volume and complexity, researchers increasingly need intuitive tools to integrate information across genomics, transcriptomics, proteomics, epigenetics, and beyond. Connected Multiomics unifies these diverse data types into a single environment, significantly reducing the time, cost, and technical barriers associated with multi-omics analysis—empowering scientists to accelerate discovery and advance precision medicine.

The platform was officially released last month following a year-long early access program that gathered valuable feedback from 40 users worldwide. At the University of Colorado Anschutz Medical School, oncology researchers leveraged Connected Multiomics to analyze proteomics data and uncover novel insights into melanoma biology. Dr. Kasey Couts, Co-Director of the CU Center for Rare Melanomas, noted: “I’m not a programmer, but this software is incredibly user-friendly. Even without deep bioinformatics expertise, my team can perform sophisticated analyses—freeing us to focus on biological interpretation rather than computational hurdles.”

“Illumina Connected Multiomics reflects our ongoing commitment to enhancing user experience across our entire software portfolio,” said Rami Mehio, Senior Vice President and General Manager of BioInsight at Illumina. “By integrating multi-omics data into a unified platform that’s accessible to biologists yet powerful enough for bioinformaticians, we enable researchers to concentrate on scientific discovery—not complex infrastructure.”

Simplifying the Multi-Omics Workflow

Connected Multiomics can integrate thousands of multi-omics samples—from both Illumina and third-party assays—in a single analysis. Built on a secure, cloud-native environment, the platform employs industry-standard statistical methods and incorporates DRAGEN secondary analysis for reproducible results. Its interactive visualization tools allow users to explore complex datasets intuitively.

Powered by Illumina’s AI-driven variant interpretation technologies—PrimateAI and PromoterAI—the platform filters out background noise early in the analysis pipeline, helping researchers prioritize biologically meaningful signals. Future updates will further enhance its AI capabilities.

Multimodal Capabilities at the Core

A cornerstone of Connected Multiomics is its support for multimodal data, including single-cell and spatial omics. The platform enables differential expression analysis, marker gene identification, and cell-type classification. In spatial transcriptomics applications, it overlays gene expression data directly onto tissue images, providing rich contextual insights into biological structure and function.

Leveraging Illumina’s industry-leading sequencing platforms, Connected Multiomics forms part of the company’s vision to deliver the most comprehensive multi-omics solution suite available. For researchers and drug developers, this integrated approach promises to catalyze the next wave of breakthroughs in precision health.

“Connected Multiomics is an accelerator,” Mehio added. “It breaks down bioinformatics barriers and helps us see biology more holistically. We’re excited to witness the discoveries our customers will make as they scale multi-omics workflows to decode the complexities of life science.”